Clinical trial · Interventional
Prospective Study on the Efficacy and Safety of 2 Week or 3 Week Xelox Regimen for Adjuvant Chemotherapy in CRC
Prospective Study on the Efficacy and Safety of 2 Week or 3 Week Xelox Regimen for Adjuvant Chemotherapy in Colorectal Patients After Surgery
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study select the diagnosis of postoperative colorectal cancer patients with stage II/III to adjuvant chemotherapy, and received 2 weeks and 3 weeks xelox adjuvant treatment process until disease progression or patients died or lost to follow-up. To analyze the difference in efficacy and safety of xelox in 2 weeks and 3 weeks of postoperative adjuvant therapy for colorectal cancer, so as to find a better postoperative adjuvant treatment model.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Capecitabine Oral Tablet [Xeloda] | Drug | Capecitabine | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- 2 week group
- interventionNames
- Drug: Capecitabine Oral Tablet [Xeloda]
- type
- ACTIVE_COMPARATOR
- label
- 3 week group
- interventionNames
- Drug: Capecitabine Oral Tablet [Xeloda]
Primary outcomes (1)
- measure
- DFS
- timeFrame
- through study completion, an average of 1 year
- description
- disease free survival
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Carcinoma of the intestine confirmed histologically or cytologically * Radical surgical resection was performed after diagnosis and the post operative stages were high-risk II or III patients * The ECOG PS score less than or equal to 2 points * No chemotherapy of any kind has been performed in the past * Neutrophils acuity 1.5x10e9/L, platelets more than 100x10e9/L, college blood red protein more than 9g/dL * liver function transaminase is less than or equal to 2.5 ULN, alkaline phosphatase is less than 2.5 ULN, and total bilirubin is less than 1.5 ULN Exclusion Criteria: * Patients with unresectable CRC * Patients who have any form of chemotherapy before * Participating in or having participated in clinical studies of other drug * Patients have second primary malignant tumors of have other malignant tumors in the past five years * There is evidence of allergic reaction to drugs in this study * A history of ischemic heart disease in the past 1 year or patients with high risk factors for heart failure, or uncontrolled arrhythmias * Severe active inflammation, including tuberculosis and HIV * Long-term immunization or hormone therapy, except hormone replacement therapy at physiological dose * Drug or alcohol addiction * Get pregnant or breastfeed * The investigator considers that the patient is not suitable for this clinical study due to any clinical or laboratory abnormalities or compliance problems
References
Publications (1)
- DERIVEDZhang H, Wang D, Tong Z, Xiang T, Zhu X, Liu L, Zheng Y, Zhao P, Fang W, Chen W. Biweekly CAPOX versus triweekly CAPOX in the adjuvant therapy of post-surgery CRC: A randomized controlled trial. PLoS One. 2025 Jul 11;20(7):e0313472. doi: 10.1371/journal.pone.0313472. eCollection 2025. PMID 40644418